414 related articles for article (PubMed ID: 35740940)
1. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
Huff SE; Winter JM; Dealwis CG
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
[TBL] [Abstract][Full Text] [Related]
2. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
Ahmad MF; Alam I; Huff SE; Pink J; Flanagan SA; Shewach D; Misko TA; Oleinick NL; Harte WE; Viswanathan R; Harris ME; Dealwis CG
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8241-8246. PubMed ID: 28716944
[TBL] [Abstract][Full Text] [Related]
3. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
4. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.
Qiu W; Zhou B; Darwish D; Shao J; Yen Y
Biochem Biophys Res Commun; 2006 Feb; 340(2):428-34. PubMed ID: 16376858
[TBL] [Abstract][Full Text] [Related]
5. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
Xie M; Yen Y; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Doetsch PW; Deng X
Cancer Res; 2014 Jan; 74(1):212-23. PubMed ID: 24197132
[TBL] [Abstract][Full Text] [Related]
6. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
Shao J; Zhou B; Zhu L; Bilio AJ; Su L; Yuan YC; Ren S; Lien EJ; Shih J; Yen Y
Biochem Pharmacol; 2005 Feb; 69(4):627-34. PubMed ID: 15670581
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.
Shao J; Zhou B; Zhu L; Qiu W; Yuan YC; Xi B; Yen Y
Cancer Res; 2004 Jan; 64(1):1-6. PubMed ID: 14729598
[TBL] [Abstract][Full Text] [Related]
8. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mannargudi MB; Deb S
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1499-1529. PubMed ID: 28624910
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.
Misko TA; Liu YT; Harris ME; Oleinick NL; Pink J; Lee HY; Dealwis CG
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):438-450. PubMed ID: 30734609
[TBL] [Abstract][Full Text] [Related]
11. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Lin ZP; Belcourt MF; Cory JG; Sartorelli AC
J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505
[TBL] [Abstract][Full Text] [Related]
12. Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
Huff SE; Mohammed FA; Yang M; Agrawal P; Pink J; Harris ME; Dealwis CG; Viswanathan R
J Med Chem; 2018 Feb; 61(3):666-680. PubMed ID: 29253340
[TBL] [Abstract][Full Text] [Related]
13. Ribonucleotide reductase inhibitors and future drug design.
Shao J; Zhou B; Chu B; Yen Y
Curr Cancer Drug Targets; 2006 Aug; 6(5):409-31. PubMed ID: 16918309
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.
Xue L; Zhou B; Liu X; Qiu W; Jin Z; Yen Y
Cancer Res; 2003 Mar; 63(5):980-6. PubMed ID: 12615712
[TBL] [Abstract][Full Text] [Related]
15. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.
Wright JA; Chan AK; Choy BK; Hurta RA; McClarty GA; Tagger AY
Biochem Cell Biol; 1990 Dec; 68(12):1364-71. PubMed ID: 2085432
[TBL] [Abstract][Full Text] [Related]
16. The structural basis for the allosteric regulation of ribonucleotide reductase.
Ahmad MF; Dealwis CG
Prog Mol Biol Transl Sci; 2013; 117():389-410. PubMed ID: 23663976
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Liu X; Zhou B; Xue L; Yen F; Chu P; Un F; Yen Y
Clin Colorectal Cancer; 2007 Jan; 6(5):374-81. PubMed ID: 17311703
[TBL] [Abstract][Full Text] [Related]
18. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the therapeutic potential of a non-natural nucleotide that inhibits human ribonucleotide reductase.
Ahmad MF; Wan Q; Jha S; Motea E; Berdis A; Dealwis C
Mol Cancer Ther; 2012 Oct; 11(10):2077-86. PubMed ID: 22933704
[TBL] [Abstract][Full Text] [Related]
20. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
